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We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for
multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was
compared with expected incidence relative to the US population. The cohort represented 13,387 person-years
at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-
years and cumulative incidences of 2.6% (95% conﬁdence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00),
and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7 years, respectively. The incidence of new cancers in the auto-
transplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/
expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were
observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P ¼ .0004), and 3.58 (99%
CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increasededgments on page 744.
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A. Mahindra et al. / Biol Blood Marrow Transplant 21 (2015) 738e745 739risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and
deﬁnes the histologic type speciﬁc risk for new cancers in patients with MM receiving post-
autotransplantation therapies, such as maintenance.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Survival of persons with multiple myeloma (MM) has
improved substantially because of new therapies, including
autotransplantations and novel drugs, such as immune-
modulating drugs and proteasome-inhibitors. Conse-
quently, it is important to determine whether there is an
increased risk of new cancers either because of the disease or
its therapy. Severaldbut not alldstudies report an increased
risk of new cancers, including acute myeloid leukemia (AML)
and myelodysplastic syndrome (MDS) in persons with
myelomawhether or not they receive autologous transplants
[1-5].
Recent data from randomized trials of lenalidomide given
after autotransplantation as maintenance therapy to prevent
relapse indicate an increased risk of new cancers. Twenty-six
of 307 in 1 study and 18 of 231 subjects in a second devel-
oped new cancers, with a signiﬁcant higher incidence in
subjects randomized to lenalidomide compared with those
receiving placebo [6,7]. A recent meta-analysis reported a
higher risk for new hematologic cancers in persons receiving
lenalidomide and melphalan [8].
The purpose of our study was to determine the baseline
incidence of new cancers after autologous transplantation in
persons with MM in the United States and to compare this
rate with those of an age-, gender-, and race-matched US
population. We also wanted to identify factors associated
with development of new cancers after autotransplantation
using statistical models.
METHODS
Subjects
Subjects receiving a ﬁrst autotransplant within 18 months of diagnosis
in the United States for MM and reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR) from 1990 to 2010 were
included in the study. The CIBMTR is a voluntary group of more than 450
transplantation centers worldwide that contribute data on allogeneic and
autologous transplantations to a statistical center at the Medical College of
Wisconsin in Milwaukee or the National Marrow Donor Program coordi-
nating center in Minneapolis, Minnesota. Participating centers are required
to register all transplantations done consecutively and post-transplantation
outcomes, including incidence of new cancer, are collected in prospective
fashion. Compliance of the participating centers is monitored by periodic
on-site audits. Subjects are followed up longitudinally, with yearly data
update. Computerized checks for errors, physicians’ review of submitted
data, and on-site audits of participating centers are used to ensure data
quality. Observational studies conducted by the CIBMTR are performed with
a waiver of informed consent and in compliance with Health Insurance
Portability and Accountability Act regulations as determined by the insti-
tutional review board and the privacy ofﬁcer of the Medical College of
Wisconsin.
Deﬁnition of Outcomes
A new cancer was deﬁned as a previously unidentiﬁed invasive cancer
occurring after transplantation. Carcinomas in situ and other precancerous
abnormalities (eg, squamous intraepithelial neoplasia) were excluded. Pa-
thology reports were obtained and reviewed centrally to conﬁrm the
diagnosis. Transplantation centers were contacted to resolve ambiguities.
After conﬁrmation, diagnoses of new cancers were coded by ICD-O-3 for
comparison with the US National Cancer Institute’s Surveillance, Epidemi-
ology, and End Results program (SEER) [9]. SEER consists of high-quality,
population-based cancer registries that are supported and sponsored by
the National Cancer Institute. The SEER program is the authoritative source
on invasive cancer incidence and survival in the United States.Statistical Analyses
Summary statistics were used to describe the cohort. For each transplant
recipient, person-years at risk were calculated from date of transplantation
until the date of last contact, death, or diagnosis of a new cancer, whichever
occurred ﬁrst. Time to diagnosis of new cancer from transplantation was
determined. Cumulative incidence of new cancers was computed at various
time points by treating death as a competing risk. Recurrence or progression
of MM was not considered a competing risk.
Age-, gender-, and race-speciﬁc cancer incidence rates derived from
SEER for all cancers combined and for cancers at speciﬁc sites were applied
to the appropriate person-years at-risk to compute the expected numbers of
cancers. Observed/expected (O/E) ratios or standardized incidence ratios
(SIRs) with 99% conﬁdence intervals (CI) were calculated on the assumption
that the observed number of cancers followed a Poisson distribution. Spe-
ciﬁc O/E ratios were not derived for nonmelanoma skin cancers and for MDS
because nonmelanoma skin cancers cancers are not collected by SEER and
MDS was not reportable to SEER until 2001. Also, there is ongoing concern
that MDS may be under-reported to SEER [10]. However, the overall inci-
dence estimates and multivariate analyses include all cancers conﬁrmed in
our study cohort.
Cox regression models were used to compare risks for various sub-
groups of transplant recipients and to identify risk factors for all new cancers
and for AML and MDS separately. Variables analyzed in the Cox model were
age at transplantation, gender, race, smoking history, Karnofsky perfor-
mance score at transplantation, body mass index (BMI), number of lines and
types of pretransplantation therapy, pretransplantation radiation, condi-
tioning regimen, whether a second autotransplantation was done, post-
transplantation maintenance therapy, and the year of transplantation.
In addition, a matched caseecontrol analysis was done comparing
autotransplantation recipients who developed a new cancer (n ¼ 163)
matched to a cohort of transplant recipients with similar follow-up who did
not develop a new cancer. Controls were matched for gender, year of
transplantation (3 years of cases), age (3 years), and follow-up interval
(<1 year, 1 to 2 years, 3 to 5 years). Controls were selected to ensure post-
transplantation follow-up time was similar and  time to development of
new cancer in the cases with the new cancer. Seven hundred seventy-six
controls were generated from the database for the 163 new cancer cases.
Separate multivariate analyses were then done to identify variables asso-
ciated with development of all new cancers and of AML/MDS. Variables
analyzed by conditional logistic regression included Karnofsky performance
score, BMI, smoking history, pretransplantation therapy, radiation therapy
before transplantation, and transplantation conditioning regimen.
RESULTS
Subjects
There were 4161 MM subjects from 164 US trans-
plantation centers contributing 13,387 person-years follow-
up (median, 2.5 years; range, .3 months to 16 years). Median
post-transplantation survival was 63 months (95% CI, 60 to
67 months), with 70% (95% CI, 68% to 72%), 52% (95% CI, 50%
to 54%), and 29% (95% CI, 26% to 31%) of subjects alive at 3, 5,
and 10 years. Subject-, disease-, and treatment-related var-
iables are summarized and described in Table 1. Median age
at transplantation was 57 years (range, 22 to 80 years), with
only 6% of subjects > 70 years. High-dose melphalan as a
single agent was the most common (81%) conditioning
regimen. As expected for a cohort spanning from 1990 to
2010, novel MM drugs were used before transplantation in
69% of subjects, including thalidomide in 34%, lenalidomide
in 14%, and bortezomib in 21%. Post-transplantation main-
tenance therapy included thalidomide (15%), lenalidomide
(11%), bortezomib (9%), and interferon (6%). Most subjects
(59%) underwent transplantation within 6 to 12 months of
diagnosis, 27% within 6 months, and 14% between 12 and
Table 1
Patient, Disease, and Treatment Characteristics
Characteristics Value
Subject-related characteristics
No. of subjects 4161
No. of centers 164
Age at transplantation, median (range), yr 57 (22-80)
<40 163 (4)
40-49 731 (18)
50-59 1611 (39)
60-69 1427 (34)
70 229 (6)
Male 2437 (59)
Race
Caucasian 3159 (76)
African American 691 (17)
Hispanic 172 (4)
Others* 78 (2)
Missing 61 (1)
Karnofsky score <90 1530 (37)
BMI
Underweight (<18.5) 39 (1)
Normal weight (18.5-25) 1045 (25)
Overweight (25-29.9) 1607 (39)
Obesity (30) 1449 (35)
Missing 21 (<1)
History of smoking before transplantation 1821 (44)
Disease-related characteristics
Stage III by Durie Salmon/international stage 2163 (52)
Immunochemical subtype of MM
IgG 2215 (53)
IgA 803 (19)
Light chain 730 (18)
Othersy 51 (1)
Nonsecretory 177 (4)
Missing 185 (4)
Albumin at diagnosis
<3.5 g/dL 1290 (31)
Creatinine at diagnosis >1.5 mg/dL 959 (23)
Hemoglobin at diagnosis < 10 g/dL 2426 (58)
Treatment characteristics
Conditioning regimens
Melphalan alone 3388 (81)
Melphalan þ TBI 206 (5)
Melphalan þ others (no TBI) 245 (6)
Busulfan þ cyclophosphamide  others 231 (6)
Othersz 91 (2)
Lines of chemotherapy before transplantation
1 2568 (62)
2 1145 (28)
>2 419 (10)
Missing 29 (<1)
Pretransplantation radiation therapy 1029 (26)
Chemotherapy before transplantation
Method I of description
VAD/high-dose steroids: yes 1684 (44)
Thalidomide: yes 1428 (34)
Bortezomib: yes 880 (21)
Lenalidomide: yes 565 (14)
Thalidomide þ bortezomib: yes 321 (8)
Bortezomib þ lenalidomide: yes 393 (9)
Melphalan þ prednisone: yes 266 (6)
Missing 29 (<1)
Method II of description
Thalidomide/lenalidomide þ bortezomib 619 (15)
Thalidomide/lenalidomide 1288 (31)
Bortezomib 261 (6)
VAD/high-dose steroids 1450 (35)
Melphalan þ prednisone 127 (3)
Others 387 (9)
Missing 29 (<1)
Sensitive to pretransplantation chemotherapy 3425 (78)
Time from diagnosis to transplantation,
median (range)
7 (<1-18)
<6 mo 1123 (27)
6-12 mo 2475 (59)
(Continued)
Table 1
(continued)
Characteristics Value
12-18 mo 563 (14)
Transplantation group
Single autotransplantation 3196 (77)
2 transplantation, time interval
between transplants < 6 mo
615 (15)
2 transplantation, time interval
between transplants  6 mo
350 (8)
Conditioning regimens
Melphalan alone 3388 (81)
Melphalan þ TBI 206 (5)
Melphalan þ others (no TBI) 245 (6)
Busulfan þ cyclophosphamide  others 231 (6)
Othersz 91 (2)
Year of transplantation
1990-1995 132 (3)
1996-1997 295 (7)
1998-1999 367 (9)
2000-2001 485 (12)
2002-2003 438 (11)
2004-2005 814 (20)
2006-2007 651 (16)
2008-2009 808 (19)
2010 171 (4)
Planned maintenance therapy
None 2333 (56)
Thalidomide 623 (15)
Bortezomib 383 (9)
Lenalidomide 450 (11)
Steroid 180 (4)
Interferon 234 (6)
Othersx 160 (4)
Missing 24 (<1)
Follow-up completeness index at 1 yr, 5 yr 97%, 82%
TBI indicates total body irradiation; VAD, vincristine, doxorubicin, dexa-
methasone.
Data presented are n (%) unless otherwise indicated.
* Other race includes: Asian/Paciﬁc islander (n ¼ 47), Native American
(n ¼ 10), Middle Eastern White (n ¼ 7).
y Other immunochemical type include IgD (n ¼ 31), IgE (n ¼ 3), IgM
(n ¼ 8).
z Other conditioning regimens include cyclophosphamide (n ¼ 12),
cyclophosphamide þ etopside (n ¼ 17), TBI (n ¼ 2),
cyclophosphamide þ taxol (n ¼ 1), cyclophosphamide þ thiotepa (n ¼ 2),
TBI þ cyclophosphamide (n ¼ 29), TBI þ thiotepa (n ¼ 9), TBI þ busulfan
(n ¼ 3), TBI þ etoposide (n ¼ 1), busulfan (n ¼ 5),
busulfan þ cytarabine þ etoposide (n ¼ 1), busulfan þ thiotepa (n ¼ 1),
carboplatin þ thiotepa (n ¼ 2).
x Other maintenance therapy includes rituxan (n ¼ 3), VP16 (etoposide)
(n ¼ 2), IVIG (n ¼ 60), cyclophosphamide (n ¼ 26), doxil (n ¼ 2), biaxin
(n ¼ 7), decadron (n ¼ 74), melphalan (n ¼ 18), taxol (n ¼ 13), cisp (n ¼ 10),
etoposide (n ¼ 4), IL2 (n ¼ 26).
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[11] for the study was more than 80%.
New Cancers
One hundred sixty-three new cancers were reported in
autotransplant recipients with a crude incidence rate of 1.2
(95% CI, 1.03 to 1.42) new cancers per 100 person-years
follow-up. The O/E ratio was 1.00 (99% CI, .81 to1.22) as
compared with the general population of the United States
(Table 2). There were 8 cases of AML, 27 of MDS, and 19 of
melanoma observed during follow-up. Cumulative inci-
dence of new cancers was 2.6% (95% CI, 2.09% to 3.17%) at
3 years and 5.09% (95% CI, 4.96% to 7.23%) at 7 years
(Figure 1, Table 3). Cumulative incidence of AML/MDS was
.5% (95% CI, .28% to .78%) at 3 years and 1.51% (95% CI, .97%
to 2.16%) at 7 years. Signiﬁcantly increased O/E ratios were
observed for AML and melanoma compared with the US
population (Table 4). Of the 163 patients with new cancers,
Table 2
Ratio of Observed to Expected Cases (O/E) of Risk of New Invasive Cancer according to Interval after Transplantation
Time Since Transplantation
<1 yr 1-2 yr 3-5 yr
No. subjects 4161 3464 2578
Person-years in risk 3849 3003 4608
New cancer site and ICD-O code O O/E 99% CI O O/E 99% CI O O/E 99% CI
Nasopharynx C11 1 22.33 .11-165.91 0 .00 .00-147.26 1 17.48 .09-129.85
Esophagus C15 0 .00 .00-10.43 0 .00 .00-12.49 2 2.85 .15-13.20
Colon C18 2 .71 .04-3.30 2 .84 .04-3.88 2 .50 .03-2.31
Rectum C19.20 0 .00 .00-3.95 1 .90 .004-6.66 1 .54 .003-4.04
Liver C22 0 .00 .00-11.34 0 .00 .00-13.75 2 3.18 .16-14.75
Pancreas C25 0 .00 .00-5.89 2 2.63 .14-12.20 1 .79 .004-5.84
Trachea, bronchus, lung C33 2 .31 .02-1.43 2 .36 .02-1.68 7 .76 .22-1.85
Other thoracic organs C37 0 .00 .00-168.71 0 .00 .00-207.75 0 .00 .00-129.04
Melanoma C43 4 2.81 .47-8.84 8 6.91 2.22-16.04 3 1.61 .18-5.88
Other skin C44 4 N/A 4 N/A 5 N/A
Soft tissue C47 1 4.86 .02-1.89 1 5.91 .03-43.92 1 3.63 .02-26.95
Breast C50 2 .41 .02-1.89 0 .00 .00-1.31 5 .78 .17-2.21
Uterus C55 0 .00 .00-277.49 0 .00 .00-336.64 0 .00 .00-211.21
Ovary C56 2 3.98 .21-18.44 0 .00 .00-12.72 0 .00 .00-7.89
Prostate C61 3 .30 .03-1.10 9 1.07 .37-2.37 6 .43 .11-1.11
Kidney C64 1 .89 .004-6.62 0 .00 .00-5.73 4 2.66 .45-8.37
Renal pelvis C65 1 17.53 .09-130.25 0 .00 .00-108.42 0 .00 .00-63.46
Ureter C66 0 .00 .00-152.01 1 33.15 .17-246.27 0 .00 .00-102.03
Bladder C67 1 .55 .002-4.05 0 .00 .00-3.38 0 .00 .00-1.99
Nervous system C70.72 0 .00 .00-11.42 1 2.63 .01-19.59 1 1.63 .01-14.37
Thyroid C73 0 .00 .00-12.44 0 .00 .00-56.12 1 1.93 .01-14.37
Hodgkin disease C81 0 .00 .00-44.13 0 .00 .00-56.12 2 13.51 .70-62.66
Non-Hodgkin disease C82 1 .67 .003-4.97 0 .00 .00-4.27 2 .98 .05-4.54
Lymphoid leukemia CC91 0 .00 .00-13.23 0 .00 .00-15.76 2 3.57 .18-16.57
AML 0 .00 .00-13.49 0 .00 .00-16.02 4 7.23 1.22-22.77
MDS 3 N/A 5 N/A 12 N/A
Overall 27 .64 .37-1.03 35 .99 .61-1.51 61 1.05 .73-1.45
Overall (excluding skin) 23 .55 .30-.92 31 .88 .53-1.38 56 .96 .66-1.35
Time Since Transplantation
6-10 11-20 Overall
No. of patients 820 110 4161
Person-year in risk 1769 158 13387
Secondary cancer site ICD-O code O O/E 99% CI O O/E 99% CI O O/E 99% CI
Nasopharynx 0 .00 .00-238.08 0 .00 .00-2510.28 2 12.32 .64-57.12
Esophagus C15 1 3.39 .02-25.18 0 .00 .00-180.73 3 1.53 .17-5.60
Colon C18 2 1.14 .06-5.30 0 .00 .00-29.09 8 .72 .23-1.67
Rectum C19.20 1 1.28 .01-9.54 0 .00 .00-69.02 3 .58 .07-2.13
Liver C22 0 .00 .00-20.77 0 .00 .00-209.09 2 1.14 .06-5.26
Pancreas C25 0 .00 .00-9.67 0 .00 .00-92.40 3 .85 .10-3.10
Trachea, bronchus, lung C33 3 .75 .08-2.74 0 .00 .00-12.86 14 .55 .24-1.05
Other thoracic organs C37 1 60.43 .30-449.08 0 .00 .00-3318.32 1 8.61 .04-63.98
Melanoma C43 3 3.80 .43-13.91 1 14.12 .07-104.93 19 3.58 1.82-6.29
Other skin C44 5 N/A 0 N/A 18 N/A
Soft tissue C47 0 .00 .00-45.52 0 .00 .00-470.11 3 3.85 .43-14.10
Beast C50 3 1.12 .13-4.12 0 .00 .00-19.38 10 .55 .20-1.17
Uterus C55 1 97.29 .49-722.91 0 .00 .00-4826.66 1 14.03 .07-104.22
Ovary C56 0 .00 .00-18.65 0 .00 .00-175.24 2 1.05 .05-4.87
Prostate C61 2 .34 .02-1.56 2 3.34 .17-15.50 22 .56 .30-.95
Kidney C64 3 4.81 .54-17.61 0 .00 .00-87.15 8 4.24 .61-4.39
Renal pelvis C65 0 .00 .00-142.68 0 .00 .00-1429.66 1 1.34 .02-34.27
Ureter C66 0 .00 .00-225.73 0 .00 .00-2218.64 1 7.00 .04-52.02
Bladder C67 1 .84 .004-6.21 0 .00 .00-46.09 2 .27 .01-1.26
Nervous system C70.72 0 .00 .00-20.61 0 .00 .00-216.10 2 1.15 .06-5.33
Thyroid C73 0 .00 .00-25.97 0 .00 .00-276.57 1 .67 .003-4.94
Hodgkin disease C81 0 .00 .00-91.85 0 .00 .00-1008.68 2 4.70 .24-21.80
Non-Hodgkin lymphoma C82 0 1.15 .01-8.56 1 11.79 .06-87.61 4 .87 .22-2.45
Lymphoid leukemia C91 1 4.11 .02-30.54 0 .00 .00-224.75 3 1.92 .22-7.02
AML 2 8.28 .43-38.41 2 83.14 4.30-385.50 8 5.19 1.67-12.04
MDS 6 N/A 1 N/A 27 N/A
Overall 34 1.38 .84-2.11 6 2.50 .62-6.29 163 1.00 .81-1.22
Overall (excluding skin) 29 1.18 .69-1.87 6 2.49 .62-6.31 145 .89 .71-1.10
ICD-O refers to the International Classiﬁcation of Diseases for Oncology. Speciﬁc O/E ratios forMDS and “other skin cancers” not calculateddseeMethods section.
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occurred before the diagnosis of new cancer. For the pa-
tients (n ¼ 71) who relapsed before the diagnosis of secondprimary cancer, median months from relapse to new cancer
was 20 months. The remaining patients (n ¼ 92) had a new
cancer diagnosis without evidence of myeloma relapse at
Figure 1. Cumulative incidence of new cancers compared with incidence of
myeloma relapse and risk of death.
Table 4
Observed/Expected Ratios for Selected New Cancers (Person-years at Risk:
13387)
Second Cancers n O/E Ratio 99% CI
Trachea/bronchus 14 .55 .24-1.05
MDS 27 85.52 48.48-138.97
AML 8 5.19 1.67-12.04
Melanoma 19 3.58 1.82-6.29
Breast 10 .55 .20-1.17
Prostate 22 .56 .30-.95
Colon 8 .72 .23-1.67
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with 17 of these relapses occurring before the diagnosis of
AML/MDS. All cases of AML were observed > 2 years after
transplantation.Table 5
Multivariate Analyses of Risk Factors for the Development of Second Primary
Malignancies among Autotransplant Recipients Who Developed a New
CancerMultivariate Analyses
Risk factors for new cancer identiﬁed using Cox regres-
sion model included older age, obesity, and male gender
(Table 5). A higher risk of new cancer was observed in sub-
jects ages 60 to 69 years compared with those < 40 years old
(hazard ratio [HR], 6.07; 95% CI, 1.48 to 24.78; P ¼ .012) and
among those >70 years (HR, 8.58; 95% CI, 1.95 to 37.74;
P¼ .005). Obesity (BMI> 30) was associated with higher risk
of developing a new cancer (HR, 1.93; 95% CI, 1.25 to 2.99;
P ¼ .003). Women had a signiﬁcantly lower risk of new
cancer compared with men (HR, .5; 95% CI, .35 to .71;
P ¼ .001). Smoking, numbers of lines of prior therapy, radi-
ation exposure for myeloma, melphalan dose (mg/m2),
receiving a second autotransplant, and post-transplantation
use of thalidomide (15% of subjects) or lenalidomide (11%
of subjects) were not signiﬁcantly associated with the overall
risk of developing a new cancer.
Multivariate analysis of AML/MDS was limited by the
relatively small number of cases (n ¼ 33). After excluding
subjects <40 years of age (only 1 case), multivariate analysis
showed age >70 years was signiﬁcantly associated with risk
of AML/MDS (HR, 13.17; 95% CI, 2.52 to 68.86; P ¼ .0022).
Case-control analyses were done on age-, gender-, and
year of transplantation-matched controls for the cases that
reported a new cancer (Table 6) to analyze additional vari-
ables. BMI > 30 remained signiﬁcant in this analysis, too,Table 3
Cumulative Incidence of New Cancers
Using Death as Competing Risk
No. at Risk Probability (95% CI)
Overall secondary cancer
At 1 yr 3465 .67 (.44-.95)
At 3 yr 1808 2.60 (2.09-3.17)
At 5 yr 823 4.21 (3.49-5.00)
At 7 yr 384 6.11 (5.08-7.24)
At 9 yr 179 7.48 (6.21-8.86)
MDS/AML
At 1 yr 3465 .07 (.01-.18)
At 3 yr 1808 .50 (.28-.78)
At 5 yr 823 .88 (.56-1.27)
At 7 yr 384 1.38 (.89-1.98)
At 9 yr 179 1.65 (1.06-2.37)with an odds ratio (OR) of 1.94 (95% CI, 1.15 to 3.26; P¼ .005).
Pretransplantation therapies for MM, conditioning regimen
(melphalan versus other agents), and post-transplantation
maintenance were not signiﬁcantly associated with
increased risk of a new cancer; smoking history and
receiving  2 lines of pretransplantation therapy were of
borderline signiﬁcance.DISCUSSION
This is the largest analysis of new cancers in auto-
transplantation recipients for MM in terms of the numbers of
new cancers analyzed and the person-years of follow up
(Table 7). The site speciﬁc ICD-O coded data in Table 2 de-
scribes risk for each cancer. The overall risk of developing an
invasive cancer after autologous transplantation for MMwas
similar to that expected among persons of similar age,
gender, and race in the general US population. The incidence
rate consistent is with other reports from auto-
transplantation studies in MM [6,12]. In contrast to the
overall new cancer risk, a clear increase in risk of myeloid
malignancies (AML/MDS) and melanoma was detected. A
prospective study by the Intergroup Francophone du
Myeloma randomizing subjects to lenalidomide or placebo
after transplantation reported a virtually identical second
cancer risk of 1.2 per 100 person-years in their placebo group
(n ¼ 307) [6].
There are several limitations to prior estimates of inci-
dence and pathogenesis of new cancers in MM, including
small numbers of subjects, inadequate follow-up, and
imperfect ascertainment of new cancers [13]. StudiesParameter HR (95% CI) P Value
Overall for risk of developing
any new cancer (n ¼ 4129)
Female versus male .50 (.35-.71) .0001
Age group Overall test P value <.0001
40-49 versus 18-39 1.62 (.36-7.13) .5240
50-59 versus 18-39 3.03 (.73-12.46) .1240
60-69 versus 18-39 6.07 (1.48-24.78) .0120
70 þ versus 18-39 8.58 (1.95-37.74) .0045
BMI Overall test P value ¼ .0048
Overweight versus
(underweight þ normal)
1.27 (.81-1.98) .2866
Obesity (BMI > 30) versus
(underweight þ normal)
1.93 (1.25-2.99) .0030
Risk of AML/MDS (n ¼ 3977)
Age group Overall test P Value ¼ .0141
50-59 versus 40-49 3.76 (.86-16.46) .0785
60-69 versus 40-49 3.95 (.88-17.70) .0730
70þ versus 40-49 13.17 (2.52-68.86) .0022
Table 6
Matched Cohort Analysis: Multivariate Odds Ratio of Developing New Cancer comparing Those Who Developed a New Cancer versus Matched Cohort of
Autotransplant Recipients Who Did Not
Variable Univariate Multivariate
n OR (95% CI) P OR (95% CI) P
KPS: 90%-100% versus 0-80% 456/280 1.37 (.93-2.03) .11 —— >.10
BMI
Normal 172 1.00 .004y 1.00 .020y
Overweight 340 1.02 (.63-1.66) .94 1.22 (.73-2.06) .519
Obesity 254 1.85 (1.14-2.98) .012 1.94 (1.15-3.26) .005
Smoker: yes versus no 374/385 1.59 (1.10-2.29) .013 1.45 (.99-2.12) .055
Lines of pretransplantation therapy: >1 versus 1 284/485 1.20 (.93-1.55) .165 1.32 (.99-1.74) .053
Radiation: yes versus no 208/561 1.07 (.72-1.59) .739 — >.10
Thalidomide: yes versus no 230/539 .74 (.48-1.14) .174 — >.10
Bortezomib: yes versus no 108/661 .94 (.48-1.82) .845 — >.10
Lenalidomide: yes versus no 53/716 .99 (.47-2.11) .985 — >.10
VAD: yes versus no 369/400 1.34 (.89-2.01) .158 — >.10
MP: yes versus no 71/698 .66 (.33-1.32) .237 — >.10
Any drug: yes versus no 672/97 .68 (.41-1.11) .119 — >.10
Conditioning regimen — >.10
Melphalan alone 623 1.00 .596z
TBI used 37 1.75 (.74-4.14) .205
BUþCY 44 .93 (.41-2.09) .86
Others 72 .96 (.50-1.85) .9079
KPS indicates Karnofsky performance status; MP, melphalan/prednisone; BU, busulfan; Cy, cyclophosphamide
*Thalidomide and Lenalidomide were not included in the model for ﬁtting “Any Drug” effect.
y 2 degrees of freedom test.
z 3 degrees of freedom test.
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factors because of the low numbers of events of interest. Our
cohort was composed of uniformly treated persons with MM
in the United States, all of whom received an upfront auto-
transplantation. The data span 2 decades, during which time
survival improved dramatically. Ascertainment and report-
ing of new cancers in our cohort was performed by the
transplantation centers with all reported new cancers
conﬁrmed by central review of pathology reports. Because
we had many new cancers, we were able to perform addi-
tional analyses to identify risk factors. Nevertheless, the
retrospective nature of the study leads to the possibility of
under-reporting of second cancers in this study.
MM in persons not receiving an autotransplantation is
reported to be associated with an increased risk of syn-
chronous and metachronous new cancers. This is also so in
untreated persons and in persons with monoclonal gamm-
opathy of undetermined signiﬁcance. A population-based
study from the Swedish Cancer Registry reported an
increased risk of skin, central nervous system, nonthyroid
endocrine neoplasms, and hematologic cancers, especially
AML, in those with MM [14]. In another study, a 2.4-fold
increased risk of MDS was reported in persons withTable 7
Comparison with New Cancers Reported from Other Major Transplantation Studie
Current (CIBMTR) CALGB 1001
Subjects, n 4161 231
Years included 1990-2010 2005-2009
Person-years at risk 13387 NR
Median age, yr 57 59
Median follow-up 48 mo 34 mo
New cancer cases 163 24
Cumulative incidence % 4.21% at 5 yr; 5.09% at 7 yr 8% LEN; 3% n
New cancer/100 person-years 1.2 NR
AML/MDS 35 7
Melanoma 19 1
NR indicates not reported; LEN, lenalidomide.monoclonal gammopathy of undetermined signiﬁcance who
had not received antimyeloma therapy [15]. An inherent risk
of MDS in MM patients has been proposed based on multi-
parameter ﬂow studies of bone marrow samples taken
before therapy [16]. These data suggest an inherent risk of
developing AML/MDS independent of therapy.
Increasing age, male gender, and obesity were associated
with an increased risk of new cancers. Increasing age and
male sex were also associated with second primary malig-
nancy development in the Intergroup Francophone du
Myeloma study [6]. In de novo AML, the age-adjusted inci-
dence is approximately 1.5-fold higher in males than it is in
females [17,18]. Males also have an increased risk of devel-
oping AML/MDS after exposure to ionizing radiation or nu-
clear weapons [19].
Increasing body mass has been associated with an
increased risk of several nonhematological cancers, ie,
esophageal, pancreas, colorectal, breast, endometrial, kidney,
thyroid, and gall bladder cancers [20]. We found that a BMI
>30 was an independent risk factor for new cancers, even in
an age- and sex-matched case-control analysis. In patients
undergoing autotransplantation for MM, there is no overall
effect of BMI on survival, progression, or nonrelapses
04 [6] IFM [7] Usmani et al. [12]
307 1148
2006-2008 1998-2007
NR 6397
55 NR
30 mo NR
32 73
o maintenance 5.5% LEN; 1% no maintenance 6.4%
3.1 LEN
1.2 No LEN
1.14
5 31
0 NR
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chemotherapy dosing. High-dose pretransplantation condi-
tioning therapy, such as high-dose melphalan, is calculated
based on weight or body surface area. Consequently, he-
matopoietic progenitor cells in persons with a higher BMI
may be exposed to more melphalan (on a dose per he-
matopoietic progenitor cells basis) than those in persons
with a lower BMI. In this case, it may not be possible to
distinguish biologic mechanisms increasing cancer risk
associated with obesity per se from those of melphalan
exposure. Although the mechanism by which obesity in-
creases the risk of new cancers is unclear, it is important as
an area of possible intervention and patient selection for
post-transplantation therapies, such as lenalidomide, that
increase the risk.
Although smoking and radiation are strong carcinogens,
they were not associated with new cancer risk in our study
[22]. This may relate to small sample size of smokers and the
overall low incidence of smoking-related cancers in the
cohort. Exposure to alkylating drugs during induction ther-
apy increases risk of new cancers in persons with MM,
especially the risk of AML/MDS [1,2,4,23]. We found no
relationship between drugs used before transplantation and
new cancer risk. However, it must be noted that our cohort
received transplants early in the course of disease with
limited duration of pretransplantation therapy.
An increased risk of AML/MDS is reported in persons with
MM in population-based nontransplantation settings
[5,13,14,23]. Because MDS was not reportable to SEER and
other cancer registries until 2001 and because of current
concern about under-reporting [10], we did not calculate the
O/E ratio speciﬁc for MDS in our study. The relatively few
cases and limited data on pretransplantation cytogenetics
also limit our analyses of MDS. Age was the only signiﬁcant
risk factor associatedwith AML/MDS, similar to that reported
for de novo AML. Interestingly, some studies report syn-
chronous AML/MDS andMM at diagnosis. Moreover, biologic
features of MDS have been described in pretherapy bone
marrow specimens using sensitive techniques [16,24,25].
Immune suppression in other settings, for example, after
kidney and heart transplantation, has been shown to corre-
late with an increased risk of developing AML [26]. Among
kidney transplant recipients, the standardized incidence ra-
tio for developing AML was 1.90 (95% CI, 1.4 to 2.4; O/E, 54/
29; P < .001), whereas among heart transplant recipients, it
was 5.10 (95% CI 3.4 to 7.1; O/E, 31/6; P < .001). In contrast to
other post-transplantation cancers, the increased risk of AML
in heart transplant recipients did not begin until 3 to 4 years
after transplantation, indicating perhaps the risk is increased
when immunosuppression is intense and prolonged.
Notably, the patients in our study were autologous
transplant recipients and not subject to further post-
transplantation immune suppression.
The increased incidence of melanoma after auto-
transplantation could reﬂect a true increase or surveillance
bias. A similar increase is reported in other transplantation
settings and in persons with immune suppression [27]. An
increased melanoma risk (SIR, 1.36) among MM patients in
the SEER registry is reported [28]. This underscores the
importance of dermatologic surveillance in the post-
transplantation setting.
The survivorship of patients withMMhas been increasing
in the era of autotransplantation and new antimyeloma
therapies, and such patients can be expected to develop sec-
ond cancers in higher numbers. A recent SEER-based analysissuggested that the risks of solid tumor cancers among MM
patients tend to rise slowly during follow-up but show little
overall difference in risk relative to the general population
(SIR, 1.02 at  60 months) [28]. In contrast, SIRs associated
withAMLaremarkedlyelevated at 24 to59months (SIR, 9.28)
and at  60 months (SIR, 10.77). We also found a continued
risk of new cancers over several years (Figure 1). Recent
studies indicating a higher risk of new cancers in persons
receiving lenalidomide had a median follow-up of 30 to
34 months [6,7]. Consequently, a true picture of long-term
risk may not have emerged in these studies and, thus,
longer follow-up of subjects is essential. Our data show the
risk of myeloma relapse is signiﬁcantly higher than the risk of
new cancers (Figure 1) and that the overall new cancer risk is
similar to that of the general population.
In conclusion, our data indicate no signiﬁcant increase in
overall risk of new cancers in persons with MM receiving
autotransplantation compared with a matched US popula-
tion. However, some cancers, such as AML and melanoma,
are signiﬁcantly increased in autotransplantation recipients
compared with a similar US population. Factors associated
with an increased risk are older age, male gender, and
obesity. The biological bases of these associations are un-
known. The risk of MM progression and death from MM
continue to exceed the risk of new cancer.
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